Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748969 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Growth Hormone in MPS I, II, and VI
A Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00748969 is a Phase 2 study that was terminated before completion, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT00748969, a Phase 2 study, was terminated before completion, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
Interventions
- DRUG Somatropin (DNA origin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748969
The ClinicalTrials.gov registry entry for NCT00748969 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Somatropin (DNA origin) is the first listed.
NCT00748969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748969 about?
NCT00748969 is a clinical study titled "Clinical Trial of Growth Hormone in MPS I, II, and VI". The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
What is the current status of trial NCT00748969?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00748969?
The interventions under investigation include: Somatropin (DNA origin) (DRUG).
Who is sponsoring clinical trial NCT00748969?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.